Boehringer Ingelheim and partner launches stage II trials for NASH and obesity
In collaboration with Zealand Pharma, Boehringer Ingelheim is advancing to stage II trials with the drug candidate BI 456906 which is currently being tested as a treatment for type II diabetes. Now, the drug will prove its worth as a treatment for the fatty liver disease NASH and obesity.
BY CHRISTOPHER DUE KARLSSON & ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
Danish biotech company Zealand Pharma and its collaborative partner, German pharmaceutical company Boehringer Ingelheim, are initiating stage II trials with the drug candidate BI 456906.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma will soon launch first drug
For subscribers
Zealand Pharma sends rescue pen on the market in late June
For subscribers
